The researchers proposed adopting a standardized framework that would outline the core elements needed for informed decision-making across cancer types.

Cancer surgery among patients older than 65 years is complex with high morbidity underscoring the need for specialized care at high-quality hospitals.

No differences seen among one-, two-, and three-year interval cancer predictions, age quartiles, or breast densities.

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and ...

A phase 2 RCT evaluated progression of prostate-specific antigen and urinary symptoms in men with low-risk prostate cancer who were administered phytochemical-rich food and Lactobacillus probiotic ...

The ESC has published a scientific statement regarding heart failure with preserved ejection fraction in patients with cancer and cancer survivors.

Rates for plans sold through federal Obamacare marketplaces will rise, on average, by 30% next year, according to a new analysis from the health research group KFF. States that run their own ...

(HealthDay News) — The US Food and Drug Administration approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or ...

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

A cross-sectional study evaluated if the mode of sexual orientation and gender identification disclosure was associated with receiving clinical resources tailored to LGBTQ+ cancer survivors.

The LITESPARK-022 and LITESPARK-011 trials evaluated combination regimens containing belzutifan in patients with advanced clear cell RCC.